An immunotherapy approach targets nanoparticles to dendritic cells of the immune system, leading to an antitumour immune response with antiviral-like features. Initial clinical tests of this approach show promise. See Letter p.396
Notes
References
Kranz, L. M. et al. Nature 534, 396–401 (2016).
Joyce, J. A. & Fearon, D. T. Science 348, 74–80 (2015).
Palucka, K. & Banchereau, J. Nature Rev. Cancer 12, 265–277 (2012).
Tel, J. et al. Cancer Res. 73, 1063–1075 (2013).
Tacken, P. J., de Vries, I. J., Torensma, R. & Figdor, C. G. Nature Rev. Immunol. 7, 790–802 (2007).
Bonifaz, L. C. et al. J. Exp. Med. 196, 1627–1638 (2002).
Bonifaz, L. C. et al. J. Exp. Med. 199, 815–824 (2004).
Tacken, P. J. et al. Blood 106, 1278–1285 (2005).
Cruz, L. J. et al. J. Control. Release 144, 118–126 (2010).
https://clinicaltrials.gov/ct2/results?term=dec-205&Search=Search
Kuhn, A. N. et al. Gene Ther. 17, 961–971 (2010).
Author information
Authors and Affiliations
Corresponding authors
Related links
Related links
Related links in Nature Research
Autoimmunity: Antigen-specific immunotherapy
Rights and permissions
About this article
Cite this article
De Vries, J., Figdor, C. Cancer vaccine triggers antiviral-type defences. Nature 534, 329–331 (2016). https://doi.org/10.1038/nature18443
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature18443
- Springer Nature Limited
This article is cited by
-
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
Nature (2020)
-
Towards superior dendritic-cell vaccines for cancer therapy
Nature Biomedical Engineering (2018)
-
A new marine-derived sulfoglycolipid triggers dendritic cell activation and immune adjuvant response
Scientific Reports (2017)
-
Engineering and physical sciences in oncology: challenges and opportunities
Nature Reviews Cancer (2017)